Ulotaront: A TAAR1 Agonist for the Treatment of Schizophrenia

[Image: see text] Ulotaront (SEP-363856) is a trace-amine associated receptor 1 (TAAR1) agonist with 5-HT1A receptor agonist activity in Phase 3 clinical development, with FDA Breakthrough Therapy Designation, for the treatment of schizophrenia. TAAR1 is a G-protein-coupled receptor (GPCR) that is e...

Descripción completa

Detalles Bibliográficos
Autores principales: Heffernan, Michele L. R., Herman, Lee W., Brown, Scott, Jones, Philip G., Shao, Liming, Hewitt, Michael C., Campbell, John E., Dedic, Nina, Hopkins, Seth C., Koblan, Kenneth S., Xie, Linghong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2021
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762745/
https://www.ncbi.nlm.nih.gov/pubmed/35047111
http://dx.doi.org/10.1021/acsmedchemlett.1c00527

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8762745/
https://www.ncbi.nlm.nih.gov/pubmed/35047111
http://dx.doi.org/10.1021/acsmedchemlett.1c00527

Ejemplares similares